Kraig Biocraft Laboratories Secures $10 Million SEPA to Support Spider Silk Production Growth and Commercialization
Kraig Biocraft Laboratories (OTCQB: KBLB) has secured a $10 million standby equity purchase agreement (SEPA) with YA II PN, (Yorkville) to support its spider silk production expansion and commercialization efforts. The agreement provides flexible access to capital over the next 36 months, with no minimum use requirements or operational restrictions.
The SEPA is designed to help bridge the company's transition to revenue generation, allowing Kraig Labs to strategically access funds for building production capacity, developing spider silk inventory, creating new consumer products, and establishing sales partnerships. The company maintains full discretion over if and when to utilize this funding.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha ottenuto un accordo di acquisto equitativo standby da 10 milioni di dollari (SEPA) con YA II PN (Yorkville) per supportare l'espansione della produzione di seta di ragno e gli sforzi di commercializzazione. L'accordo offre un accesso flessibile al capitale per i prossimi 36 mesi, senza requisiti minimi di utilizzo o restrizioni operative.
Il SEPA è progettato per aiutare a colmare la transizione dell'azienda verso la generazione di entrate, consentendo a Kraig Labs di accedere strategicamente ai fondi per aumentare la capacità produttiva, sviluppare l'inventario di seta di ragno, creare nuovi prodotti per i consumatori e stabilire partenariati di vendita. L'azienda mantiene piena discrezionalità su se e quando utilizzare questo finanziamento.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha asegurado un acuerdo de compra de capital standby de 10 millones de dólares (SEPA) con YA II PN (Yorkville) para apoyar la expansión de su producción de seda de araña y los esfuerzos de comercialización. El acuerdo proporciona acceso flexible a capital durante los próximos 36 meses, sin requisitos mínimos de uso ni restricciones operativas.
El SEPA está diseñado para ayudar a puentear la transición de la empresa a la generación de ingresos, permitiendo a Kraig Labs acceder estratégicamente a fondos para aumentar la capacidad de producción, desarrollar inventario de seda de araña, crear nuevos productos para consumidores y establecer asociaciones de ventas. La empresa mantiene plena discreción sobre si y cuándo utilizar este financiamiento.
크라이그 바이오크래프트 연구소 (OTCQB: KBLB)는 스파이더 실크 생산 확대 및 상용화를 지원하기 위해 YA II PN(요크빌)와 천만 달러 규모의 스탠바이 자본 구매 계약(SEPA)을 체결했습니다. 이 계약은 36개월 동안 최소 사용 요구 사항이나 운영 제한 없이 자본에 유연하게 접근할 수 있도록 합니다.
SEPA는 회사를 수익 창출로 전환하는 데 도움을 주기 위해 설계되었으며, 크라이그 연구소가 생산 능력을 구축하고, 스파이더 실크 재고를 개발하며, 새로운 소비자 제품을 만들고, 판매 파트너십을 구축하는 데 필요한 자금을 전략적으로 접근할 수 있게 합니다. 회사는 이 자금을 언제, 어떻게 사용할지에 대해 전적인 재량을 가집니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a sécurisé un accord d'achat d'équité de standby de 10 millions de dollars (SEPA) avec YA II PN (Yorkville) pour soutenir l'expansion de sa production de soie d'araignée et ses efforts de commercialisation. L'accord offre un accès flexible à des fonds au cours des 36 prochains mois, sans exigences minimales d'utilisation ni restrictions opérationnelles.
Le SEPA est conçu pour aider à franchir la transition de l'entreprise vers la génération de revenus, permettant à Kraig Labs d'accéder stratégiquement à des fonds pour augmenter sa capacité de production, développer son inventaire de soie d'araignée, créer de nouveaux produits de consommation et établir des partenariats de vente. L'entreprise conserve toute discrétion sur le fait d'utiliser ou non ce financement.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat eine Kapitalvereinbarung über 10 Millionen Dollar (SEPA) mit YA II PN (Yorkville) gesichert, um die Erweiterung und Kommerzialisierung der Spinnenseideproduktion zu unterstützen. Die Vereinbarung ermöglicht einen flexiblen Zugang zu Kapital über die nächsten 36 Monate hinweg, ohne Mindestnutzungsanforderungen oder betriebliche Einschränkungen.
Die SEPA wurde entwickelt, um den Übergang des Unternehmens zur Umsatzgenerierung zu überbrücken, sodass Kraig Labs strategisch Mittel zur Erhöhung der Produktionskapazität, zur Entwicklung von Spinnenseidenvorräten, zur Schaffung neuer Konsumgüter und zur Etablierung von Vertriebspartnerschaften anfordern kann. Das Unternehmen behält die volle Kontrolle darüber, ob und wann es dieses Kapital nutzen möchte.
- Secured $10 million in flexible funding through SEPA
- No minimum use requirements or operational restrictions
- 36-month access window to capital
- Company maintains full control over funding utilization
- Potential shareholder dilution through equity-based funding
- Company still in pre-revenue phase requiring external funding
ANN ARBOR, Mich., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a leading developer of spider silk-based fibers, announces that it has secured
Kraig Labs structured the SEPA to allow the Company to access capital over the next 36 months, when and how it determines best for the growth of spider silk production and end-market development. The Company is under no obligation to utilize this funding, has no minimum use requirements, and it does not impose any restrictions on the Company's operations. This agreement gives the Company the flexibility to access the capital necessary to bridge its transition to revenue generation.
“We have worked with Yorkville in the past and we are excited to renew and strengthen that relationship. This strategic financial relationship provides Kraig Labs with the flexibility to support the growth of spider silk commercialization," said Founder and CEO, Kim Thompson. "The SEPA provides access to significant growth capital, allowing us to focus on executing our vision for eco-friendly, cost-effective spider silk production. We will put this capital to work, building out our production capacity and spider silk inventory, developing new consumer products, and establishing partnerships with market channel sales partners."
For details about other recent advancements the Company has made, please see the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
The securities described herein have not been registered under the Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the value and duration of KBLB's new standby equity purchase agreement?
How will KBLB use the funds from the $10M SEPA agreement?
Are there any minimum usage requirements for KBLB's SEPA funding?
How does the SEPA agreement impact KBLB shareholders?
What is the purpose of KBLB's $10M SEPA funding?
